A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

NCT07030517 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Teclistamab

Sponsor

Johnson & Johnson Private Limited